The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 1×
“Cytochrome P450 1A2 (CYP1A2) accounts for about 15% of the total P450 content in the liver [1] and metabolises several important clinical drugs, such as clozapine [2], verapamil [3] and endogenous substrates such as melatonin [4] and estradiol [5].”
BackgroundSachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Coffee, CYP1A2 genotype, and risk of myocardial infarction
Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., & Campos, H. (2006) · JAMA · doi:10.1001/jama.295.10.1135 · Cited by 490 · cited 1×
“Despite the fact that CYP1A2*1F is argued to have an effect on enzyme inducibility, a recent study reported an association between coffee intake and an increased risk of nonfatal myocardial infarction among individuals carrying the CYP1A2*1F allele, who are defined as slow metabolisers, in both smokers and non-smokers…”
BackgroundNakajima, M., Yokoi, T., Mizutani, M., Kinoshitah, M., Funayama, M., & Kamataki, T. (1999) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022352 · Cited by 346
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
Bertilsson, L., Carrillo, J., Dahl, M.-L., LLerena, A., Alm, C., Bondesson, U., Lindström, L., de la Rubia, I. R., Ramos, S., & Benítez, J. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04385.x · Cited by 307
Self-citationRasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241 · cited 1×
“A study on monozygotic and dizygotic twins revealed that variations in CYP1A2 activity are mainly governed by genetic factors although environmental factors also play a role [8].”
BackgroundCaffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking
Kalow, W., & Tang, B.-K. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.8 · Cited by 213
Identification of P450 enzymes involved in metabolism of verapamil in humans
Kroemer, H., Gautier, J.-C., Beaune, P., Henderson, C., Roland Wolf, C., & Eichelbaum, M. (1993) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00169164 · Cited by 200
Impairment of Caffeine Clearance by Chronic Use of Low-Dose Oestrogen-Containing Oral Contraceptives
Abernethy, D. R., & Todd, E. L. (1985) · European Journal of Clinical Pharmacology · doi:10.1007/bf00544361 · Cited by 195 · cited 2×
“Previous studies have shown that smoking induces CYP1A2 [7] via the aryl hydrocarbon receptor and that OCs inhibit CYP1A2 [9].”
BackgroundYamazaki, H., Shaw, P. M., Guengerich, F. P., & Shimada, T. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970217f · Cited by 182
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Evidence for epigenetic regulation of CYP1A2 expression was shown by measuring the extent of DNA methylation of a CpG island close to the translation start site, which was inversely correlated to hepatic CYP1A2 mRNA levels (Ghotbi et al., 2007; Dobrinas et al., 2011).”
BackgroundResultInfluentialIngelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Self-citationPolymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
International society of sports nutrition position stand: caffeine and performance
Goldstein, E. R., Ziegenfuss, T., Kalman, D., Kreider, R., Campbell, B., Wilborn, C., Taylor, L., Willoughby, D., Stout, J., Graves, B. S., et al. (2010) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-7-5 · Cited by 686
International Society of Sports Nutrition Position Stand: Caffeine and Exercise Performance
Guest, N. S., VanDusseldorp, T. A., Nelson, M. T., Grgic, J., Schoenfeld, B. J., Jenkins, N. D. M., Arent, S. M., Antonio, J., Stout, J. R., Trexler, E. T., et al. (2021) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-020-00383-4 · Cited by 665
Scientific Opinion on the safety of caffeine
EFSA Panel on Dietetic Products, N. A. A. (. (2015) · EFSA Journal · doi:10.2903/j.efsa.2015.4102 · Cited by 613
“CYP1A2 enzyme induction and higher caffeine clearance in smokers have also been reported in other studies (Joeres et al., 1988; Ghotbi et al., 2007).”
ResultFunctional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
The neuroprotective effects of caffeine in neurodegenerative diseases
Kolahdouzan, M., & Hamadeh, M. J. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12684 · Cited by 302
The clinical toxicology of caffeine: A review and case study
Willson, C. (2018) · Toxicology Reports · doi:10.1016/j.toxrep.2018.11.002 · Cited by 289
de Leon, J., Schoretsanitis, G., Smith, R. L., Molden, E., Solismaa, A., Seppälä, N., Kopeček, M., Švancer, P., Olmos, I., Ricciardi, C., et al. (2022) · Pharmacopsychiatry · doi:10.1055/a-1625-6388 · Cited by 275
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J.-P. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 262
Pharmacokinetics and metabolism of natural methylxanthines in animal and man
Arnaud, M. J. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_3 · Cited by 259
Southward, K., Rutherfurd-Markwick, K. J., & Ali, A. (2018) · Sports Medicine · doi:10.1007/s40279-018-0939-8 · Cited by 254
Gunes, A., & Dahl, M.-L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.625 · Cited by 256
Caffeine, CYP1A2 Genotype, and Endurance Performance in Athletes
GUEST, N., COREY, P., VESCOVI, J., & EL-SOHEMY, A. (2018) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001596 · Cited by 231
Grzegorzewski, J., Bartsch, F., Köller, A., & König, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752826 · Cited by 108
“However, satisfying genetic or epigenetic markers-on the CYP1A locus on chromosome 15 could not be found by follow-up studies (Jiang et al., 2006; Ghotbi et al., 2007; Gunes and Dahl, 2008; Klein et al., 2010; Yang et al., 2010).”
BackgroundKoonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0011-3 · Cited by 100
Silva, H., Del Coso, J., & Pickering, C. (2025) · Sports Medicine · doi:10.1007/s40279-025-02245-y · Cited by 21
“Specifically, individuals who are homozygous for the AA genotype at this genetic variant exhibit faster capacity to metabolize caffeine into paraxanthine and other dimethylxanthines compared with those with the CA or CC genotypes [106].”
Metadata
- Authors
- Ghotbi, R., Christensen, M., Roh, H.-K., Ingelman-Sundberg, M., Aklillu, E., & Bertilsson, L.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2007-03-17
- Volume
- 63
- Issue
- 6
- Pages
- 537-546
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2049033995
- Cited by
- 264
- References
- 27
- FWCI
- 13.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.